Nautilus Biotechnology, Inc. (NAUT)Healthcare | Biotechnology | Seattle, United States | NasdaqCM
1.78 USD
-0.11
(-5.820%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 1.81 +0.03 (1.685%) ⇧ (July 13, 2026, 7:48 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:37 a.m. EDT
The investment case for Nautilus Biotechnology is currently broken by a catastrophic multi-year decline and deteriorating fundamentals. Over the last four years, the stock has lost over 92% of its value, with the most recent annual performance showing a massive drop of nearly 69%. While the company recently secured a customer for its Tau assay and insiders are buying, these positive developments are insufficient to counteract the market's verdict on the business's trajectory. The balance sheet shows significant losses and negative free cash flow, and the negative earnings per share indicate the company is not yet profitable. With no dividend to provide income and a price chart that has been in a relentless freefall, there is no margin of safety here. The options market confirms this pessimism, with traders loading up on long-dated puts to protect against further drops rather than buying calls for a rebound. Until the company demonstrates sustained profitability and a reversal in its multi-year price trend, this remains a speculative trap rather than a viable investment. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.106410 |
| AutoTheta | 0.111922 |
| AutoETS | 0.111925 |
| AutoARIMA | 0.139042 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 4.41 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.207 |
| Excess Kurtosis | 0.09 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.993 |
| Market Cap | 226,200,368 |
| Forward P/E | -2.41 |
| Beta | 0.81 |
| Previous Name | ARYA Sciences Acquisition Corp III |
| Website | https://www.nautilus.bio |
As of July 11, 2026, 6:37 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside speculation. Call volume and open interest are negligible across all expirations, while put open interest is concentrated significantly further out in time (December) compared to the near term. This distribution suggests a 'buy the dip' strategy where investors are hedging against further declines rather than betting on a recovery. The implied volatility for puts is notably higher than calls, reinforcing the fear of continued weakness.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.3984771 |
| Address1 | 2,701 Eastlake Avenue East |
| All Time High | 25.886 |
| All Time Low | 0.62 |
| Ask | 2.3 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 2,015,310 |
| Average Daily Volume3 Month | 650,522 |
| Average Volume | 650,522 |
| Average Volume10Days | 2,015,310 |
| Beta | 0.805 |
| Bid | 1.34 |
| Bid Size | 2 |
| Book Value | 1.136 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.78 |
| Current Ratio | 11.846 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 1.9 |
| Day Low | 1.78 |
| Debt To Equity | 19.993 |
| Display Name | Nautilus Biotechnology |
| Earnings Call Timestamp End | 1,785,268,800 |
| Earnings Call Timestamp Start | 1,785,268,800 |
| Earnings Timestamp | 1,785,241,800 |
| Earnings Timestamp End | 1,785,241,800 |
| Earnings Timestamp Start | 1,785,241,800 |
| Ebitda | -62,495,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.547 |
| Enterprise Value | 159,204,368 |
| Eps Forward | -0.74 |
| Eps Trailing Twelve Months | -0.43 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 2.3913 |
| Fifty Day Average Change | -0.6113 |
| Fifty Day Average Change Percent | -0.25563502 |
| Fifty Two Week Change Percent | 139.8477 |
| Fifty Two Week High | 4.31 |
| Fifty Two Week High Change | -2.53 |
| Fifty Two Week High Change Percent | -0.587007 |
| Fifty Two Week Low | 0.62 |
| Fifty Two Week Low Change | 1.16 |
| Fifty Two Week Low Change Percent | 1.8709676 |
| Fifty Two Week Range | 0.62 - 4.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,596,807,000,000 |
| Float Shares | 55,809,221 |
| Forward Eps | -0.74 |
| Forward P E | -2.4054053 |
| Free Cashflow | -28,882,124 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 127 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.33206 |
| Held Percent Institutions | 0.40733 |
| Implied Shares Outstanding | 127,078,855 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington. |
| Long Name | Nautilus Biotechnology, Inc. |
| Market | us_market |
| Market Cap | 226,200,368 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_568970644 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-13 |
| Net Income To Common | -57,085,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 240,179,035 |
| Number Of Analyst Opinions | 1 |
| Open | 1.86 |
| Operating Cashflow | -49,859,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 206 333 2001 |
| Post Market Change | 0.029999971 |
| Post Market Change Percent | 1.6853917 |
| Post Market Price | 1.81 |
| Post Market Time | 1,783,986,480 |
| Prev Name | ARYA Sciences Acquisition Corp III |
| Previous Close | 1.89 |
| Price Hint | 4 |
| Price To Book | 1.5669013 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.491 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.11 |
| Regular Market Change Percent | -5.82011 |
| Regular Market Day High | 1.9 |
| Regular Market Day Low | 1.78 |
| Regular Market Day Range | 1.78 - 1.9 |
| Regular Market Open | 1.86 |
| Regular Market Previous Close | 1.89 |
| Regular Market Price | 1.78 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 845,104 |
| Return On Assets | -0.19766001 |
| Return On Equity | -0.33693 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 127,078,855 |
| Shares Percent Shares Out | 0.0064999997 |
| Shares Short | 829,522 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 760,157 |
| Short Name | Nautilus Biotechnology, Inc. |
| Short Percent Of Float | 0.013300001 |
| Short Ratio | 0.97 |
| Source Interval | 15 |
| State | WA |
| Symbol | NAUT |
| Target High Price | 4.0 |
| Target Low Price | 4.0 |
| Target Mean Price | 4.0 |
| Target Median Price | 4.0 |
| Total Cash | 95,869,000 |
| Total Cash Per Share | 0.754 |
| Total Debt | 28,873,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.43 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.178945 |
| Two Hundred Day Average Change | -0.3989451 |
| Two Hundred Day Average Change Percent | -0.18309094 |
| Type Disp | Equity |
| Volume | 845,104 |
| Website | https://www.nautilus.bio |
| Zip | 98,102 |